Combination Correctors and Potentiators for Cystic Fibrosis: A Systematic Review and Meta-analysis

Karol Basta; Chris John

doi:10.38192/1.6.1.c7

Vol. 6 No. 1 (2020), Conference Abstracts

Vol. 6 No. 1 (2020)

Combination Correctors and Potentiators for Cystic Fibrosis: A Systematic Review and Meta-analysis

Conference Abstracts

https://doi.org/10.38192/1.6.1.c7

Published 2019-11-27

Karol Basta⁺⁻
Chris John⁺⁻

Karol Basta

Imperial College London, UK

Chris John

Imperial College London, UK

PDF

Keywords

cystic fibrosis
Phe508del mitation
combination correctors
potentiators

How to Cite

Basta, K., & John, C. (2019). Combination Correctors and Potentiators for Cystic Fibrosis: A Systematic Review and Meta-analysis . The Physician, 6(1), c7. https://doi.org/10.38192/1.6.1.c7

Abstract

The most common cause of cystic fibrosis (CF) is the Phe508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, resulting in CFTR’s reduced trafficking, targeted by correctors, and reduced functioning, targeted by potentiators. For the majority of CF patients, the combination correctors and potentiators (CCPs) lumacaftor/ivacaftor and tezacaftor/ivacaftor, are the only treatments licensed to target the disease origin.

https://doi.org/10.38192/1.6.1.c7

PDF